Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Reporter French Polynesia.
Press releases published on October 21, 2025
RadNet to Host Investor Day on November 11, 2025
LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of outpatient imaging centers and digital health and AI solutions, today …
PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes
Mesquite, NV, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV — October 21, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP) subsidiary PrestoDoctor, a national leader in cannabis telehealth and patient-care certification services, today announced its official …
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker to safely achieve patient plasma levels suitable for high …
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732, was found to be well-tolerated, confirmed target engagement and …
Acies Bio doubling biomanufacturing capacity with the construction of 30 m³ bioreactor
KAMNIK, Slovenia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Acies Bio has begun the project for construction of facility with expanded fermentation and DSP capabilities with the largest 30 m³ bioreactor yet, marking a significant step in expanding its large-scale …
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Saint-Genis-Pouilly, France, 21 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer, Philip Beer, will be presenting data on the identification …
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3G Eleva successfully completed the Single Ascending Dose part of the First-in-Human clinical trial evaluating CPV-104 in healthy volunteers …
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile – STAMFORD, Conn., Oct. 21, …
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an …
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1 Data will be shared with regulatory authorities to support regulatory filings …
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside …
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onderdeel van de voortdurende transformatie van het bedrijf
Deze intentie volgt na een uitgebreid strategisch evaluatieproces en zou de meest optimale manier zijn om kapitaal toe te wijzen ter ondersteuning van een sterkere en duurzame toekomst voor Galapagos Mechelen, België; 21 oktober 2025, 07:30 CET; …
Phonak’s AI revolution continues: new Infinio Ultra hearing aids with clearer sound and easier maintenance
STÄFA, Switzerland, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, introduces Infinio Ultra, the next step in tackling two core challenges for hearing aid users: speech clarity from any direction and wax …
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced the pricing of …
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Silicone Market worth $33,246.3 million by 2030, at a CAGR of 5.2%, says MarketsandMarkets™
Delray Beach, FL, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Silicone Market was worth USD 24,502.4 million in 2024 and is projected to reach USD 33,246.3 million by 2030, at a CAGR of 5.2%, as per the recent study by MarketsandMarkets™. Silicone is a high- …